艾裏德克斯 IRIX 深 滬
交易中 08-10 11:50:37 美东时间
0.8817
+0.051
+6.16%
華盛通- 最 高0.9199
- 今 開0.83
- 成交量 4.59万股
- 最 低 0.8242
- 昨 收 0.8305
- 總市值 1534.73万
- 52周最高 1.6481
- 市盈率 靜 --
- 換手率 0.26%
- 52周最低 0.8041
- 委 比 90.39%
- 總股本 1740.65万
- 歷史最高 16.64
- 量 比 3.03
- 振 幅 11.52%
- 歷史最低 0.782
- 每 手 1
- 風險率 0.18%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Iridex Expands Its EyeProGPO Product Offering To Include The Company’s Line Of EndoProbe Handpieces
Through the agreement, more than 4,300 EyeProGPO members will have access to preferred pricing on Iridex EndoProbe Handpieces, expanding the value Iridex provides to ophthalmology practices, ambulatory surgery centers, and hospitals across the United States. The addition builds on Iridex’s existing ...
07-20 19:14
Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering
Iridex Corporation expands its EyeProGPO product offering to include its EndoProbe® Handpieces, providing over 4,300 EyeProGPO members with preferred pricing. The addition enhances access to Iridex's retina laser portfolio for ophthalmology practices and surgical centers. The EndoProbe Handpieces are single-use devices for treating retinal disorders, available in various configurations. Both Iridex and EyeProGPO emphasize their commitment to adva...
07-20 11:00
Iridex Adjourns 2026 Annual Meeting, Plans July Reconvening
Iridex ( ($IRIX) ) has provided an announcement. On June 12, 2026, Iridex Corpo...
06-19 04:33
Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference
<p>Iridex Corporation, a global leader in laser-based medical systems for treating glaucoma and retinal diseases, announced its participation in the Planet MicroCap Las Vegas 2026 Conference. Management will present on June 17, 2026, at 4:00 pm PT. The presentation will be available live and archived on the company’s website. Iridex specializes in innovative laser technologies, including its MicroPulse® system, used for treating glaucoma and diab...
06-09 20:05
电话会总结 ｜ Iridex(IRIX)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据IRIDEX业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** 2026年第一季度总营收1,180万美元，与去年同期基本持平（去年同期1,190万美元），符合公司此前指引预期。 **盈利能力：** 毛利润470万美元，毛利率40%；营业费用510万美元；营业亏损30万美元；净亏损50万美元（每股亏损0.03美元）。 **现金状况：** 截至2026年4月4日，现金及现金等价物460万美元，本季度现金减少140万美元。 ## 2. 财务指标变化 **营收变化：** - 同比：总营收基本持平（-0.8%） - 产品线表现
05-20 12:13
Iridex Q1 2026 Earnings Call: Complete Transcript
Iridex (NASDAQ:IRIX) released first-quarter financial results and hosted an ear...
05-20 05:49
Iridex Affirms FY2026 Sales Guidance of $51.000M-$53.000M vs $53.227M Est
Iridex (NASDAQ:IRIX) affirms FY2026 sales outlook from $51.000 million-$53.000 million to $51.000 million-$53.000 million vs $53.227 million estimate.
05-20 04:18
Iridex Q1 EPS $(0.03) Beats $(0.07) Estimate, Sales $11.799M Miss $11.910M Estimate
Iridex (NASDAQ:IRIX) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.07) by 57.14 percent. This is a 70 percent increase over losses of $(0.10) per share from the same
05-20 04:17
Iridex Reports First Quarter 2026 Financial Results
Iridex Corporation reported first-quarter 2026 revenue of $11.8 million, a 1% decrease from the prior year, driven by lower retina product sales. The Cyclo G6 product family revenue grew 14% to $3.6 million, while retina product revenue declined 12% to $5.8 million. Operating expenses decreased 4% to $5.1 million, and the net loss narrowed to $0.5 million, or $0.03 per share. The company reaffirmed its full-year 2026 revenue guidance of $51 milli...
05-19 20:05
